Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those of hospitals, a new drug company-funded study says.
The study was funded by drug maker Gilead Sciences, whose products include treatments for HIV/AIDS and hepatitis often prescribed by 340B grantee entities. Berkeley Research Group, the company that established drug industry 340B contract pharmacy policy administrator 340B ESP, conducted the study released on May 22. Gilead Chair and CEO Daniel O’Day is PhRMA’s board chair-elect.
Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those of hospitals, […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
